Organization & Developments: Marker Therapeutics

Parents

2018: Marker Therapeutics: Buy, Sell, Or Hold?
2019: Biotech Analysis Central Preview Series: Marker Therapeutics
2020: Revisiting Marker Therapeutics
2021: Marker Therapeutics: Passing Through A Catalyst Desert
2021: Marker Therapeutics: Undervalued Cancer Therapeutics With High Potential
2022: Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications.
The company specializes in developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.